# **European HIV Vaccine Alliance (EHVA):** an EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates

*- Fact Sheet January 2016*

## OUR CHALLENGES:

Despite enormous progress in the prevention and treatment of HIV/AIDS, the global response cannot keep pace: 35 million people are living with HIV worldwide with ca 6,000 new infections each day. Numerous HIV prevention strategies (such as PrEP and PEP), though proven successful, are difficult to sustain long-term. A vaccine still represents the most effective tool in the combat against HIV from a public health perspective. To date, many prophylactic and therapeutic vaccine concepts have been developed and several efficacy trials have been conducted but with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at the early stage of vaccine development to mitigate the risks of failure.

## EHVA APPROACH

To address these complex and challenging scientific issues, EHVA aims to develop a Multidisciplinary Vaccine Platform through a global and innovative alliance notably:

- Multidisciplinary expertise from vaccine discovery, to immune monitoring to clinical development
- State-of-the-art innovative technologies to profile immune responses and virus reservoir
- Access to large cohort studies bringing together top European clinical centres in the fields of prophylactic and therapeutic vaccines
- Access to a panel of experimental HIV vaccines under clinical development as benchmark
- Liaison with African leading scientists/programs fostering future testing of EHVA vaccines in Sub-Saharan Africa
- Engagement of industrial expertise for downstream vaccine development

## EHVA OBJECTIVES

EHVA plans to develop and implement:

- **Discovery Platform** with the goal of generating novel vaccine candidates inducing potent neutralizing and non-neutralizing antibody responses and T-cell responses
- **Immune Profiling Platform** with the goal of ranking novel and existing (benchmark) vaccine candidates on the basis of the immune profile
- **Data Management/Integration/Down-Selection Platform**, with the goal of providing statistical tools for the analysis and interpretation of complex data and algorithms for the efficient selection of vaccines
- **Clinical Trials Platform** with the goal of accelerating the clinical development of novel vaccines and the early prediction of vaccine failure.

## ABOUT EHVA

EHVA brings together **39 partners** from 11 countries in Europe, 4 in Sub-Sahara Africa and the US, involving leading scientists in the fields of molecular biology, structure biology, vectorology, adjuvants, delivery, immunology, clinical science and biostatistics.

Furthermore, EHVA bridges **industrial expertise** with academic excellence by engaging directly world leading pharmaceutical companies in the consortium, a partnership essential for the discovery and development of an effective vaccine.

EHVA is coordinated by the Institut national de la santé et de la recherche médicale (INSERM) and the scientific leadership is carried out conjointly with the Lausanne University Hospital (CHUV).

EHVA is a 5 year project funded by the European Union's Horizon 2020 Research and Innovation Programme under the grant agreement no. 681032.

European Commission

## EHVA partners



Institut national de la santé et de la recherche médicale France
Lausanne University Hospital CHUV Switzerland
Sanofi Pasteur SA France
Consorci Institut d'Investigacions Biomèdiques August Pi i Sunyer Spain
Heinrich-Pette Institut Leibniz Institut für Experimentelle Virologie Germany
Imperial College of Science, Technology and Medicine UK
Istituto Superiore di Sanità Italy
Universitat Regensburg Germany
Karolinska Institutet Sweden
Universität Zürich Switzerland
Fondazione per l'Istituto di Ricerca in Biomedicina Switzerland
Universitätsklinikum Hamburg-Eppendorf Germany
The Chancellor, Masters and Scholars of the University of Oxford UK
Université Joseph Fourier Grenoble France
Academisch Medisch Centrum bij de Universiteit van Amsterdam the Netherlands
Stichting Biomedical Primate Research Center the Netherlands
Klinikum der Universität München Germany
Medizinische Universität Innsbruck Austria
Agencia Estatal Consejo Superior de Investigaciones Cientificas Spain
Université de Lausanne Switzerland
Erasmus Universitair Medisch Centrum Rotterdam the Netherlands
Stichting International AIDS Vaccine Initiative the Netherlands
FIT Biotech Oy Finland
EuroVacc Foundation Switzerland
Fred Hutchinson Cancer Research Center Non Profit Corporation US
Commissariat à l'énergie atomique et aux énergies alternatives France
Universität Bern Switzerland
Janssen the Netherlands
Uganda Virus Research Institute Uganda
National Institute for Medical Research Tanzania
Instituto Nacional de Saude Mozambique
Association PAC-CI Cote d'Ivoire
University College London UK
University of Liverpool UK
The General Hospital Corporation US
Vrije Universiteit Brussel Belgium
Istituto Nazionale Malattie Infettive L.Spallanzani - IRCCS Italy
European AIDS Treatment Group (EATG) Belgium
Inserm Transfert France